Qlife Completes Customer-Funded Feasibility Study and Evaluates Potential Next Development Phase

Qlife Holding AB ("Qlife" or the "Company") today announces the successful completion of a customer-funded feasibility study focused on evaluating the applicability of the Egoo® platform within a new therapeutic area requiring regular biomarker monitoring.

As announced on 1 June 2026, Qlife entered into a customer-funded feasibility study with a global pharmaceutical company. The study has now been completed as planned, marking a further step in demonstrating the versatility of the Egoo platform and its potential applicability beyond current development programs.

The objective of the study was to assess the technical feasibility of adapting the Egoo platform to support decentralized monitoring of a clinically relevant biomarker in a patient population that today relies primarily on centralized laboratory testing. The completed work included analytical evaluation, prototype adaptation, sample handling assessment, and initial performance testing.

The study confirmed the potential of the Egoo platform to address the intended application and provided valuable technical, regulatory, and product development insights to support future activities.

Following completion of the feasibility phase, Qlife and its customer are currently evaluating potential next steps. These may include additional feasibility activities focused on further optimization and risk reduction, as well as a potential transition into a broader product development program. No decisions have yet been made regarding the scope or timing of future phases.

"The completion of this feasibility study represents an important milestone for Qlife and further validates the flexibility of the Egoo platform," said Thomas Warthoe, CEO of Qlife Holding AB. "Importantly, the project was fully funded by the customer and has enabled us to explore a new application area while generating valuable know-how and development experience. We look forward to continuing the dialogue regarding potential future collaboration."

The feasibility program forms part of Qlife's broader strategy to establish Egoo as a platform technology capable of supporting decentralized biomarker monitoring across multiple disease areas and therapeutic indications.

The information was submitted for publication through the agency of the contact person set out above on 29-09-2026 12:24 CET

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

About Egoo®

Egoo is Qlife's proprietary platform for decentralized biomarker testing. The system is designed to enable laboratory-quality analysis from a small blood sample in near real time and supports the Company's vision of bringing clinical testing closer to patients, healthcare professionals, and pharmaceutical partners.